This page shows the latest Truxima news and features for those working in and with pharma, biotech and healthcare.
One bright spot for the company this week was the US launch of Celltrion-partnered Truxima – the first biosimilar of Roche’s big-selling Rituxan (rituximab) to reach the US market –
period. A number of biosimilar versions of the drug hit European markets last year, including Celltrion's Truxima, (pictured), marketed by Mundipharma and other firms across the region, and this year
This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera. ... With Remsima, we achieved market
Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab).
It was the second biosimilar of Roche's drug to be approved in Europe after Celltrion/Mundipharma's Truxima, which also pipped Sandoz to the filing post in the US after
It followed that this year by gaining approval from the European Commission for the world’s first monoclonal antibody biosimilar of MabTera (rituximab), marketed as Truxima.
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....